samsung

FDA approves third Herceptin biosimilar with Samsung Bioepis’ Ontruzant

pharmafile | January 22, 2019 | News story | Manufacturing and Production, Sales and Marketing FDA, Herceptin, Samsung Bioepis, biosimilar, pharma 

Samsung Bioepis’ has announced that the FDA has chosen to approve Ontruzant (trastuzumab-dttb), its biosimilar version of Roche’s Herceptin (trastuzumab), in the same indications as its reference product.

This includes three cancer indications: as an adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer and metastatic gastric cancer or gastroesophageal junction adenocarcinoma in patients who have not received prior treatment for metastatic disease.

The decision marks the first approval of an oncology biosimilar for Samsung Bioepis. The therapy secured approval in Europe in November last year. Ontruzant now joins Mylan’s Ogivri and Celltrion’s Herzuma as the third Herceptin biosimilar approved in the US.

“For many cancer patients in the US, battling cancer has not only been a health issue, but a considerable financial burden brought on by cancer treatment,” commented Sang-Jin Pak, Senior Vice President and Head of Commercial Division at Samsung Bioepis. “Biosimilars are intended to be lower cost, high-quality treatment options that have the potential to alleviate such burden. We sincerely hope our trastuzumab biosimilar will do exactly that.”

Advertisement

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

FDA grants De Novo authorisation to light-filtering device for migraine

The US Food and Drug Administration (FDA) has granted De Novo marketing authorisation to Avulux, …

The Gateway to Local Adoption Series

Latest content